维普期刊资源整合服务平台（V6.5）

154篇 您的检索式：作者名="Body S"

选中清除导出查看参考文献查看引证文献引用追踪共8页首页上一页第1页下一页末页 /8 跳转

	题名	作者	年代	出处	被引量
1	Abnormal pulmonary granuloma formation in osteopontin-deficient mice显示文摘	Hayden JM Body S	2001	Am J Respir Crit Care Med2001，164，1：	1
2	Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay显示文摘	Body R Carley S McDowell G		0，，：	1
3	PKC412-a protein kinase in hibitor with a broael therapeutic potential显示文摘	Fabbro D Ruetz S Bodis S	2000	Anticancer Drug Res2000，15，1：	1
4	Environmental-geochemical mapping program in the Slovak Republic显示文摘	Rapant S Raposova M Bodis D	1999	Journal of Geochemical Exploration1999，66，2：	1
5	coli cytoplasm 显示文摘	LAVALLIE ER DIBLASIO EA KOVACIC S l A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E	1993	Biotechn ology1993，11，2：	1
6	Environmental-geochemical mapping program in the Slovak Repub- lic显示文摘	RAPANT S RAPOSOVA M BODIS D	1999	Journal of Geochemical Exploration1999，66，2：	1
7	Evidence for the release and possible neural regulation of nitric oxide in human saliva显示文摘	HAREGEWOIN A	1993	Biochem Biophys Res Commun1993，194，1：	1
8	Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial 显示文摘	Pecherstorfer M Rivkin S Body JJ	2006	Clin Drug Investig2006，26，6：	1
9	Environmental-geochemical mapping program in the Slovak Republic显示文摘	Rapant S Raposova M Bodis D	1999	Journal of Geochemical Exploration1999，66，2：	1
10	PKC412-a protein kinase inhihitor with a broad therapeutic potential显示文摘	Fabbro D Ruetz S Bodis S	2000	Anticancer Drug Des2000，15，1：	1
11	PKC412-a protein kinase inhihitor with a broad therapeutic potential显示文摘	Ruetz S Bodis S	2000	Anticancer Drug Des2000，15，1：	1
12	Management and costs of treating lung cancer patients in a university hospital显示文摘	Dedes K J Szues T D Bodis S	2004	Pharmacoeeonomics2004，22，7：	1
13	Apoptosis and the prognostic significance of p53 mutation显示文摘	lowe SW Bodis S Bardeesy N	1994	Cold Spring Harb Symp Quant Bio11994，59，6：	1
14	Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay显示文摘	Body R Carley S MeDowell G	2011	J Am Coll Cardiol2011，58，：	1
15	p53 status and the efficacy of cancer therapy in vivo显示文摘	Lowe SW Bodis S McClatchey A	1994	Science1994，266，5186：	1
16	Management of cancertreatment-induced bone loss in early breast and prostate cancer : aconsensus paper of the Belgian Bone Club 显示文摘	Body JJ Bergmann P Boonen S	2007	Osteoporos Int2007，18，11：	1
17	O-ral ibandronate is as active as intravenous zoledronic acidfor reducing bone turnover markers in women with breastcancer and bone metastases显示文摘	BODY J J LICHINITSER M TJULANDIN S	2007	Ann Oncol2007，18，7：	1
18	Long term safety of intravenous ibandronate for up to 4 years in metastatic breast cancer: an open label trial 显示文摘	Pecherstorfer M Rivkin S Body JJ	2006	Clin Drug lnvestig2006，26，6：	1
19	Connexin expression and gap-junction-mediated cell interactions in an in vitro model of haemopoietic stroma显示文摘	Hurtado S P Balduino A Bodi E C	2004	Cell Tissue Res2004，316，1：	1
20	Determination of the minimal clinically important difference in the FIM instrument in patients with stroke 显示文摘	Beninato M Gill - Body KM Salles S	2006	Arch Phys Med Rehabil2006，87，1：	1

返回顶部每页显示：

共8页首页上一页第1页下一页末页 /8 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示